^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Small Cell Lung Cancer
    Drug:Bavencio (avelumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer (PAVE)

    Excerpt:
    ...Patients must have an available recently-obtained, formalin-fixed, paraffin-embedded (FFPE) tissue sample containing tumor (biopsy preferably within 6 months) or a minimum number of 10 unstained slides, suitable for PD-L1 expression assessment...
    Trial ID:
    PAVE